Best Practices in Statistical Process Monitoring of Biopharmaceutical Manufacturing Operations
|
|
- Neil Lamb
- 8 years ago
- Views:
Transcription
1 IBC Process2Product Oct 4th, 2011 Best Practices in Statistical Process Monitoring of Biopharmaceutical Manufacturing Operations Amer Pompe disease Jack Prior Sr. Director, BioProcess Engineering Technical Operations
2 BPOG Out of Trend/Statistical Process Control Working Group Steve Jones (BPOG) Bill Henry (GSK) Kevin Legg (Genzyme) Brian Stamper (MedImmune) Janet Alvarado (Merck) Monica Jungen (Merck-Serono) Paul McCormac (Pfizer) Christoph Hoh (Sanofi) Dave Hopkins (Genzyme) Jarrod Medeiros (Merck-Serono) Michael Warncke (Bayer) Cenk Undey (Amgen)
3 Origins: BPOG Data Analysis Working Group BioPhorum Operations Group (BPOG) 13 companies & ~300 participants Collaborating on biopharmaceutical MFG challenges Point Share organized on Data Analysis (October 2010, Boston, MA) Case studies/discussion: process monitoring, platforms/tools, organizations Point Share Observations Struggling with similar challenges Diverse approaches in place and contemplated Companies in process of defining SPC practices & standards Follow-up Focus on SPC and OOT Teleconferences Internal surveys Best practice sharing How can we summarize.process2product
4 Converging Drivers for Formal Statistical Process Monitoring Business Drivers Technical Support Mission cgmp Requirements Lean Avoid Surprises Preempt OOS Global supply chains CMO/tech transfers Biosimilars QbD Understand Control Improve Continuous Process Verification ICH Q10 Cost 2011
5 SPC Driver - FDA Validation Guidance: Continued Process Verification Continually assure the commercial process remains in a state of control Establish ongoing program to analyze product and process data Recommends Data statistically trended and reviewed by trained personnel Statisticians/equivalent with adequate SPC training develop plans Quality unit review
6 SPC Driver - ICH Q10: Pharmaceutical Quality System plan and execute system for monitoring of process performance and product quality Analyze parameters and attributes identified in control strategy to verify continued operation within a state of control continued capability of processes and controls data management and statistical tools identify sources of variation for continuous improvement enrich the design space
7 Goals of Effective SPC Program Efficient and proactive management of process o Enhance quality compliance and process understanding o Preempt deviations, don t generate them Balanced focus on process parameters and analytics o Focus effort on critical areas o Reduce effort on non-critical items Have the appropriate people looking at the appropriate data analyzed in the appropriate way responding in the appropriate manner, Kevin Legg, Genzyme
8 Key Questions Raised in Working Group on SPC implementation Strategy 1. How to decide what to formally trend? 2. How to respond to OOT Signals? 3. How to manage OOT Response? 4. How to define out of trend? 5. How to set (and reset) limits and on what reference data? 6. How to deal with unusual baseline data? 7. How to choose what statistical rules to apply? 8. How to learn more?
9 1. How to Choose which Variables to Trend? Define Process Control Strategy (PCS) 1 Break process into defined steps with defined purposes (the why vs. how ) Classify Process Control Elements (CPP, KPP, CQA, CI, PI ) PCS shapes monitoring strategy & signal response Formally trend/monitor CQAs (IPCs, ISs, Specs) and CPPs Set proportionate formality/response for process and consistency indicators 1 A planned set of controls, derived from current product and process understanding that assures process performance and product quality. (ICH Q10). Paul MaCormac, Pfizer
10 2. How to Respond to OOT Signals: Specification, Action, and Statistical Control Limits Specification Limit: Voice of Customer Set based on process capability, regulatory expectations and product safety concerns Action Limits: PV Acceptance Criteria, Batch record limits Statistical Control Limit: Voice of Process +/- 3 for n> 15 and/or PpK 1.33 Set based on process characterization and/or large scale data Paul MaCormac
11 2. How to Respond to OOT Signals: Potential Map from PCS Classification to Signal Response Variable Acceptable Range Normal Operating Range Statistical Control Limits Attributes CQAs* Specification/IS In-Process Control (IPC) Consistency Indicator (later) Process Indicator (real-time) Critical Deviation Major Deviation deviation N/A N/A Technical review DCS Alarm OOT/ APR Review Immediate alert OOT / APR Review Immediate alert Technical review Immediate alert Aggregate as CI Potential MVA** Parameters Critical Process Parameter (CPP)* Key process parameter (highly controlled) Non-KPP(nKPP) (no step impact) Major Deviation deviation DCS Alarm DCS Alarm Technical review Potential MVA Technical review Potential MVA *Defined in ICH Q8 **Multivariate Analysis
12 3. How to Manage OOT Response? Survey comments QC Lab If no confirmed lab error, QC triggers deviation If lab error, initial result invalidated after new result obtained Lab error sometimes only detected in CI calculation (e.g. yield outliers) Process Parameters & Consistency Indicators Manufacturing, technical, or (sometimes) validation responsibility Immediately enter in quality system OR trigger discussion OOT below a set performance level can be agreed as non-concern If uncovered during APR, investigation may be launched Frequency of Data Review Automate/alert after each discrete observation if possible Cross-functional notification can facilitate resolution Periodic data reviews for continuous data (e.g. run reviews) Formal evaluation may not occur until APR
13 3. How to Manage OOT Response? Team Structure Basis for Extent of Investigation Risk assessment & variable classification Potential impact to process performance and product quality Upfront work in Process Control Strategy (PCS) guides actions
14 4. How to Define Out of Trend? Variation not explained by a single distribution of process output 1 Violation of the Western Electric or Nelson trending rules 2 Result from a process not associated with random variation Visual review...outside 3 discretion of lab management Can vary by site or group within site (i.e. QC vs. manufacturing) Consensus on +/- 3 limits but from what data set? 1. MJ Kiemele et al. Basic Statistics: Tools for Continuous Improvement.4 th Edition 2. NIST/SEMATECH e-handbook of Statistical Methods, / 04MAY2011
15 5. How and When to Define Control Limits? Choose right reference data set After ~15-30 batches from stable process (Shewhart recommends 25+) Use interim provisional limits from process validation criteria Use largest dataset representative of current process & testing Exclude Outliers Remove known root (special) causes Use objective outlier exclusion methods Use judgement -> tighter limits (conservative, defendable, appropriate?) Show outliers even if excluded from calculations Revisit/adapt when needed When known process or analytical change impacts mean or variability As APR recommendation or in change control Can shift mean but retain long term variance
16 6. How to Handle Unusual Data? Situation out of control historical data non-normal historical data LoQ assays (e.g. LaL, purity) Strategies/Comments Exclude special cause variability Incorporate all common cause variability Short horizon reference range often too narrow Utilize moving range for control limit calculations. 3 limits often apply 1 Avoid complex WE/Nelson rules Transform data prior to applying rules Visually inspect trends instead If sufficient data is available >LoQ, exclude <LoQ Otherwise, use percentile approach 1 Wheeler, Normality and the process behavior chart, SPC Press
17 7. When & How to use Western Electric/Nelson Rules? Detecting Common vs. Special Cause Variation Short Horizon Common Cause Assay noise Raw materials Procedural noise Long Horizon Common/Special Cause (Not visible in 25 points) Lab transfers Reagent lots Personnel Column packing Upstream productivity Plant utilization Special Cause Operator errors Equipment failures Sample handling Data typos/calibration Material instability Data rarely independent and identically distributed Real processes trend/move - resulting in false signals 3 and 2/3 outside 2 rules OK - complex rules often inappropriate Backward looking rules impact earlier lots Trend signals slow in bio environment (e.g. 6 batches in a row) Value of well-trained eyes on right parameters
18 8. How to Learn More? Regulatory Guidance ICH Q9 International Conference on Harmonization (ICH) Q10: Section 3.2 ICH Q11 (Draft): Section 3.2, Section 6.1 New Process Validation Guidance Statistical Process Control DS Chambers, D Wheeler, Understanding Statistical Process Control DC Montgomery, Introduction to statistical quality control. 6 th Ed. MJ Kiemele et al, Basic Statistics: Tools for Continuous Improvement. 4th Ed. NIST/SEMATECH e-handbook of Statistical Methods, / 04MAY2011 William A. Levinson, Statistical Process Control for Real-World Applications, CRC Press
19 Summary: Key Success Factors in SPC Implementation Infrastructure Data management to enable trending and ensure data integrity Appropriate state of control to enable decisions based on trended data Quality Systems & Business Processes Proper OOT definition, notification methods, and proportional response Defined responsible parties to ensure timely response to OOT Process Control Strategy Appropriate risk-based classification of parameters and attributes Statistical tools/methods to ensure right limits and rules applied Focus on preventing deviations Knowledge capture
Process Validation: Practical Aspects of the New FDA Guidance
Process Validation: Practical Aspects of the New FDA Guidance ISPE Boston Chapter Meeting April 18, 2013 Rusty Morrison Commissioning Agents, Inc. Objectives / Summary What is Process Validation? Regulatory
More informationProduct Quality Management
Product Quality Management Deborah Baly, Ph.D Sr. Director, Commercial Product Quality Management, GNE/ROCHE 1 Presentation Outline: Product Quality Management Regulatory landscape and need for integrated
More informationImplementing Lifecycle Validation Practices at Contract Manufacturing Organizations
Implementing Lifecycle Validation Practices at Contract Manufacturing Organizations This paper discusses the nuances of lifecycle validation implementation at contract manufacturing organizations (CMOs).
More informationPharmaceutical Product Quality, Quality by Design, cgmp, and Quality Metrics
Pharmaceutical Product Quality, Quality by Design, cgmp, and Quality Metrics Lawrence X. Yu, Ph.D. Deputy Director Office of Pharmaceutical Quality Center for Drug Evaluation and Research Food and Drug
More informationProcess Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle
Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle A LIFECYCLE Approach to Process Validation? Lifecycle [ICH Q8(R2)]: All phases
More informationCommercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations
Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Kevin O Donnell PhD Market Compliance Manager, IMB PDA / FDA Conference Pharmaceutical
More informationWhat to control? CQAs and CPPs
What to control? CQAs and CPPs Dr. Thomas Stangler On behalf of the European Generic medicines Association Development Strategy & Technology Manager Sandoz Biopharmaceuticals 1 Martin Schiestl Singapore,
More informationPharmaceutical Quality Systems: US Perspective
Pharmaceutical Quality Systems: US Perspective Rick Friedman Associate Director, Office of Manufacturing and Product Quality Center for Drug Evaluation and Research Topics Background: The ICH Q10 Pharmaceutical
More informationQuality by Design Approaches to Analytical Methods -- FDA Perspective. Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011
Quality by Design Approaches to Analytical Methods -- FDA Perspective Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011 1 Outline What is Quality by Design (QbD) Role of Analytical
More informationICH Q10 - Pharmaceutical Quality System
WCC PDA Dinner Meeting Jan 2012 ICH Q10 - Pharmaceutical Quality System Neil Wilkinson NSF-DBA www.nsf-dba.com ICHQ10.1 WCC PDA Dinner Meeting Jan 2012 Your Presenter Partner at NSF-DBA USA Training, Consultancy,
More informationQuality by Design (QbD) Overview
Quality by Design (QbD) Overview Gary Warren Director, Haemostasis and Thrombosis R&D October, 2015 CSL Behring Pty Ltd Broadmeadows, Victoria What is Quality by Design (QbD)? QbD is: A Quality System
More informationWorkshop on process validation
Workshop on process validation General concepts on process validation Kowid Ho Scope / background Process evaluation/validation of biotechnology derived proteins used as active substance in the manufacture
More informationGuidance for Industry
Guidance for Industry Q8, Q9, and Q10 Questions and Answers(R4) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationMoving from Quality Control to Quality Assurance (Proactive Compliance!)
Moving from Quality Control to Quality Assurance (Proactive Compliance!) Guy Wingate, VP & Compliance Officer Global Manufacturing & Supply, GlaxoSmithKline Disclaimer The views and opinions expressed
More informationPost-Approval Change Management: Challenges and Opportunities An FDA Perspective
CMC Workshop From Drug Development to Global Supply to Patients April 15-17, 2013, Washington, DC Post-Approval Change Management: Challenges and Opportunities An FDA Perspective Christine M. V. Moore,
More informationLab to Patient Model Implementing a Recipe Based Framework to Support Product Lifecycle Management
Lab to Patient Model Implementing a Recipe Based Framework to Support Product Lifecycle Management Adam Fermier, Gerry Collins, Kevin Crean (& Spirit Team), John Cunningham, Thomas Difeo, John Dingerdissen,
More informationGuidance for Industry. Q10 Pharmaceutical Quality System
Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation
More informationRisk based monitoring using integrated clinical development platform
Risk based monitoring using integrated clinical development platform Authors Sita Rama Swamy Peddiboyina Dr. Shailesh Vijay Joshi 1 Abstract Post FDA s final guidance on Risk Based Monitoring, Industry
More informationMultivariate Tools for Modern Pharmaceutical Control FDA Perspective
Multivariate Tools for Modern Pharmaceutical Control FDA Perspective IFPAC Annual Meeting 22 January 2013 Christine M. V. Moore, Ph.D. Acting Director ONDQA/CDER/FDA Outline Introduction to Multivariate
More informationTopic 3 RISK MANAGEMENT APPROACH for CMC SUBMISSIONS AND REVIEW. Topic Leaders Kim Huynh-Ba, Pharmalytik Lynn Gold, Camargo
Topic 3 RISK MANAGEMENT APPROACH for CMC SUBMISSIONS AND REVIEW Topic Leaders Kim Huynh-Ba, Pharmalytik Lynn Gold, Camargo Introduction to Speakers John Duan, Clinical Pharmacology & Biopharmaceutics Reviewer,
More information21ST CENTURY PROCESS MANAGEMENT USING SPC BASED MANUFACTURING ANALYTICS
WHITE PAPER 21ST CENTURY PROCESS MANAGEMENT USING SPC BASED MANUFACTURING ANALYTICS By Jeffrey L. Cawley, Vice President Market Development, Northwest Analytics Inc. Actively using SPC and Manufacturing
More informationThe Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence
The Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence CMC Strategy Forum, Sorrento, May 7th, 2014 Susanne Ausborn, Pharma Technical Regulatory Policy F. Hoffmann-La Roche,
More informationGuidance for Industry
Guidance for Industry Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationAddressing Risk in Partner / Contractor Selection and Onboarding. Michael Davidson VP Quality Systems and Compliance March 2014
Addressing Risk in Partner / Contractor Selection and Onboarding Michael Davidson VP Quality Systems and Compliance March 2014 Industry Trends Pfizer Overview Pfizer s Approach Risk Based Robust Due Diligence
More informationState of Control Over the Lifecycle and Process Validation (New and Legacy Products)
State of Control Over the Lifecycle and Process Validation (New and Legacy Products) Grace McNally Branch Chief (acting), Regulatory Policy and Collaboration Branch FDA/CDER/Office of Compliance ICH Q10,
More informationMaking Improvement Work in Pharmaceutical Manufacturing Some Case Studies. Ronald D. Snee
Making Improvement Work in Pharmaceutical Manufacturing Some Case Studies Ronald D. Snee ISPE Midwest Extended Education and Vendor Day Overland Park, KS 2 May 2007 King of Prussia PA New York NY Washington
More informationPatient Centric Monitoring Methodology
Patient Centric Monitoring Methodology The ICON approach to risk based monitoring in clinical trials An ICON White Paper Introduction The pharmaceutical and CRO industries are undergoing a radical shift
More informationQuality Takes Lead in MOM Software Deployments and Performance Benefits
Quality Takes Lead in MOM Software Deployments and Performance Benefits 1 Quality Takes Lead in MOM Software Deployments and Performance Benefits See the scope of MOM-focused Quality Management software
More informationICH Q10 and Change Management: Enabling Quality Improvement
ICH Q10 and Change Management: Enabling Quality Improvement Bernadette Doyle PhD Vice President and Head of Global Technical Group Global Manufacturing and Supply GlaxoSmithKline Overview Drivers for Change
More informationTechnology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)
M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over
More informationICH guideline Q8, Q9 and Q10 - questions and answers volume 4
December 2010 EMA/CHMP/ICH/265145/ Committee for medicinal products for human use (CHMP) ICH guideline Q8, Q9 and Q10 - questions and answers volume 4 Step 5 Transmission to CHMP for information December
More informationUsing Statistical Process Control (SPC) for improved Utility Management
Using Statistical Process Control (SPC) for improved Utility Management Scott Dorner Hach Company Manage and Transform data into information to gain efficiencies 1 Data, Data Everywhere We track enormous
More informationPHARMACEUTICAL QUALITY SYSTEM Q10
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10 Current Step
More informationBiomanufacturing Vision for the Future
Biomanufacturing Vision for the Future Shou-Bai Chao, Ph.D. Senior Vice President Global Manufacturing and Technical Operations MedImmune (a Div of AstraZeneca) NIPTE/FDA Research Conference Future of
More informationA Comprehensive Model For Manufacturing Analytics
Presented at the WBF North American Conference Atlanta, GA March 5-8, 2006 195 Wekiva Springs Road, Suite 200 Longwood, FL 32779-2552 +1.407.774.5764 Fax: +1.407.774.6751 E-mail: info@wbf.org www.wbf.org
More informationAligning Quality Management Processes to Compliance Goals
Aligning Quality Management Processes to Compliance Goals MetricStream.com Smart Consulting Group Joint Webinar February 23 rd 2012 Nigel J. Smart, Ph.D. Smart Consulting Group 20 E. Market Street West
More informationAspen InfoPlus.21. Family
Aspen InfoPlus.21 Family The process industry s most comprehensive performance management and analysis solution for optimizing manufacturing and improving profitability The Aspen InfoPlus.21 Family aggregates
More informationPutting SPC to Work in Manufacturing: Reducing Variability and Increasing Productivity
Putting SPC to Work in Manufacturing: Reducing Variability and Increasing Productivity White Paper John Clemons, Director of Manufacturing IT MAVERICK Technologies, LLC Introduction... 3 From Data to Diagnostics...
More informationConducting a Gap Analysis on your Change Control System. Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc.
Conducting a Gap Analysis on your Change Control System Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc. Standards, Regulations, Guidelines related to Change Control Management
More informationApplying Statistics Recommended by Regulatory Documents
Applying Statistics Recommended by Regulatory Documents Steven Walfish President, Statistical Outsourcing Services steven@statisticaloutsourcingservices.com 301-325 325-31293129 About the Speaker Mr. Steven
More informationCalibration & Preventative Maintenance. Sally Wolfgang Manager, Quality Operations Merck & Co., Inc.
Calibration & Preventative Maintenance Sally Wolfgang Manager, Quality Operations Merck & Co., Inc. Calibration: A comparison of two instruments or measuring devices one of which is a standard of known
More informationVariables Control Charts
MINITAB ASSISTANT WHITE PAPER This paper explains the research conducted by Minitab statisticians to develop the methods and data checks used in the Assistant in Minitab 17 Statistical Software. Variables
More informationThe Advantages of Enterprise Historians vs. Relational Databases
GE Intelligent Platforms The Advantages of Enterprise Historians vs. Relational Databases Comparing Two Approaches for Data Collection and Optimized Process Operations The Advantages of Enterprise Historians
More informationBiotechnology Manufacturing Analytics
Cory Brown Dermot McCaul Rob Kasprow, PhD SAP Adaptive Manufacturing Summit September 2009 Chicago, IL Biotechnology Manufacturing Analytics Vaccine Manufacturing Operations IT Account Manager Vaccine
More informationAdopting Site Quality Management to Optimize Risk-Based Monitoring
Adopting Site Quality Management to Optimize Risk-Based Monitoring Medidata and other marks used herein are trademarks of Medidata Solutions, Inc. All other trademarks are the property of their respective
More informationQbD Considerations for Analytical Methods - FDA Perspective
QbD Considerations for Analytical Methods - FDA Perspective IFPAC Annual Meeting Baltimore, January 25, 2013 Sharmista Chatterjee, Ph.D. CMC Lead for QbD ONDQA/CDER/FDA Outline Role of analytics in drug
More informationAssay Qualification Template for Host Cell Protein ELISA
Assay Qualification Template for Host Cell Protein ELISA Introduction: With ever increasing importance being placed on host cell protein (HCP) removal during the purification process, it is critical to
More informationQuality Takes Lead in MOM Software Deployments and Performance Benefits
Quality Takes Lead in MOM Software Deployments and Performance Benefits Although meeting production demand has been and always will remain the central focus of manufacturers, over time, other business
More informationChange Management for Virtual Pharmaceutical Firms. Randall Tlachac Molecular and Cellular Therapeutics
Change Management for Virtual Pharmaceutical Firms Randall Tlachac Molecular and Cellular Therapeutics Opening Considerations Managing the kinds of changes encountered by and instituted between two organizations
More informationThe Advantages of Plant-wide Historians vs. Relational Databases
GE Intelligent Platforms The Advantages of Plant-wide Historians vs. Relational Databases Comparing Two Approaches for Data Collection and Optimized Process Operations The Advantages of Plant-wide Historians
More informationBest Practices In Ensuring Quality Standards When Outsourcing To Contract Manufacturers, Licensees And Consultants
Best Practices In Ensuring Quality Standards When Outsourcing To Contract Manufacturers, Licensees And Consultants Alex D. Kanarek, PhD BioProcess Technology Consultants, Inc. Strategic Institute Quality
More informationASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 038-1 26 March 2012 AIDE-MEMOIRE ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION PIC/S March 2012 Reproduction
More informationSPC Data Visualization of Seasonal and Financial Data Using JMP WHITE PAPER
SPC Data Visualization of Seasonal and Financial Data Using JMP WHITE PAPER SAS White Paper Table of Contents Abstract.... 1 Background.... 1 Example 1: Telescope Company Monitors Revenue.... 3 Example
More informationDedicated and calibrated pipettes can reduce variability. The Most Expensive Test is a Retest By Ruth Noe, UK and Ireland Sales Manager
LALreview LAL REVIEW: PUBLISHED BY LONZA 2008 Issue 3 EDITOR S COLUMN What is the most expensive endotoxin test that you run in your QC lab? If I were to guess, I would say the retest. How often do you
More informationWelcome Computer System Validation Training Delivered to FDA. ISPE Boston Area Chapter February 20, 2014
Welcome Computer System Validation Training Delivered to FDA ISPE Boston Area Chapter February 20, 2014 1 Background Training Conducted on April 24, 2012 Food & Drug Administration Division of Manufacturing
More informationGAMP5 - a lifecycle management framework for customized bioprocess solutions
GE Healthcare Life Sciences GAMP5 - a lifecycle management framework for customized bioprocess solutions imagination at work GE Healthcare s engineering department, Customized Bioprocess Solutions (CBS),
More informationLloyd F. Colegrove Mary Beth Seasholtz Bryant LaFreniere
Lloyd F. Colegrove Mary Beth Seasholtz Bryant LaFreniere 1 Run Design - Mountains of Data Planning Wisdom Improvement Marketing Trailer Current Data Use Poor coordination, no obvious plan. We work, data
More informationCLINICAL TRIALS: FOCUS VS. DRIVING EFFICIENCIES BLINDLY
www.5amsolutions.com CLINICAL TRIALS: FOCUS VS. DRIVING EFFICIENCIES BLINDLY Continuing downward pressures on healthcare economics, diminished outcomes, patent cliffs, and antiquated R&D models are among
More informationOptimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy
Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy Global Pharma Sourcing Conference December 6-7, 2011 Philadelphia, USA Nigel J. Smart, Ph.D. Smart Consulting
More informationEstablishing Asset Management Metrics to Drive Business Improvements
Establishing Asset Management Metrics to Drive Business Improvements An Industry White Paper Dan Roessler, Industry Marketing, Aspen Technology, Inc. About AspenTech AspenTech is a leading supplier of
More informationCompliance Control Procedure Execution Management System Reduces Compliance Risks by 10X
Compliance Control Procedure Execution Management System Reduces Compliance Risks by 10X By John Helfrich, VelQuest Corporation INTRODUCTION The top drug GMP violations in 2009 involved failings in manufacturers'
More informationQbD Approach to Assay Development and Method Validation
QbD Approach to Assay Development and Method Validation Thomas A. Little Ph.D. 11/105/2014 President Thomas A. Little Consulting 12401 N Wildflower Lane Highland, UT 84003 1-925-285-1847 drlittle@dr-tom.com
More informationCOMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS
COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance
More informationTo avoid potential inspection
Good Analytical Method Validation Practice Deriving Acceptance for the AMV Protocol: Part II To avoid potential inspection observations for test method validations by the regulatory agencies, it has become
More informationCorrective and Preventive Actions
Corrective and Preventive Actions A Five Step Approach Topics to Be Covered What is CAPA? Governing authority Five steps to a good CAPA process Where companies have difficulty Example citations Recap What
More informationTitle:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions
WELCOME Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions Contents: Introduction GMP Audit GMP Audit plan GMP Auditing
More informationA Better Statistical Method for A/B Testing in Marketing Campaigns
A Better Statistical Method for A/B Testing in Marketing Campaigns Scott Burk Marketers are always looking for an advantage, a way to win customers, improve market share, profitability and demonstrate
More informationICH Q 10 Pharmaceutical Quality System PQS DIA China Annual Meeting, May 2010
ICH Q 10 Pharmaceutical Quality System PQS DIA China Annual Meeting, May 2010 Joseph C. Famulare Head of External Relations and Collaboration Pharma Global Technical Operations Global Quality, F. Hoffmann-La
More informationWorkshop B Control Strategy
ICH-GCG ASEAN Workshop B Control Strategy Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference on Harmonisation
More informationApplication of Quality Risk Management to Pharmaceutical Operations. Eldon Henson, Vice President, Quality Operations
Application of Quality Risk Management to Pharmaceutical Operations Eldon Henson, Vice President, Quality Operations Key Topics of Discussion Definition of Quality Risk Management (QRM) Overview of PDA
More informationBarnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA
Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA This presentation is the property of DynPort Vaccine Company LLC, a CSC company, and
More informationCourse Overview Lean Six Sigma Green Belt
Course Overview Lean Six Sigma Green Belt Summary and Objectives This Six Sigma Green Belt course is comprised of 11 separate sessions. Each session is a collection of related lessons and includes an interactive
More informationInternational GMP Requirements for Quality Control Laboratories and Recomendations for Implementation
International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation Ludwig Huber, Ph.D. ludwig_huber@labcompliance.com Overview GMP requirements for Quality Control laboratories
More informationORACLE CONSULTING GROUP
ORACLE CONSULTING GROUP 9 Golder Ranch Rd., Ste. 1 Tucson, Arizona 9 Web Site: E-mail: 20-2-0 20-2-0 (FAX) CONSULTING MEMORANDUM QUALITY SYSTEM INSPECTION TECHNIQUE
More informationSection 1 Project Management, Project Communication/Process Design, Mgmt, Documentation, Definition & Scope /CRO-Sponsor Partnership
Section 1 Project Management, Project Communication/Process Design, Mgmt, Documentation, Definition & Scope /CRO-Sponsor Partnership PROJECT MANAGEMENT - SCOPE DEFINITION AND MANAGEMENT Understands the
More informationDesign of Experiments for Analytical Method Development and Validation
Design of Experiments for Analytical Method Development and Validation Thomas A. Little Ph.D. 2/12/2014 President Thomas A. Little Consulting 12401 N Wildflower Lane Highland, UT 84003 1-925-285-1847 drlittle@dr-tom.com
More informationThe Effective Management of Change Across the ICHQ10 Lifecycle
The Effective Management of Change Across the ICHQ10 Lifecycle Rob Hughes AstraZeneca 1 Change Management the guide This presentation will: describe a structured approach to change across the ICH Q10 lifecycle
More informationAssay Development and Method Validation Essentials
Assay Development and Method Validation Essentials Thomas A. Little Ph.D. 10/13/2012 President Thomas A. Little Consulting 12401 N Wildflower Lane Highland, UT 84003 1-925-285-1847 drlittle@dr-tom.com
More informationthrough advances in risk-based
Insight brief Quintiles is a market leader with >100 risk-based monitoring studies Quintiles developed solutions that bring as much as 25% cost reduction over traditional trial execution approaches Transform
More informationTRAINING TITLE: CAPA System Expert Certification (CERT-003)
TRAINING TITLE: CAPA System Expert Certification (CERT-003) OVERVIEW: Medical devices, biopharmaceutical, and traditional drug manufacturing companies devote an important part of their resources dealing
More informationStatistical Process Control (SPC) Training Guide
Statistical Process Control (SPC) Training Guide Rev X05, 09/2013 What is data? Data is factual information (as measurements or statistics) used as a basic for reasoning, discussion or calculation. (Merriam-Webster
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION
April 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES:
More informationWelcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to
Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to introduce you to the concepts behind risk-based monitoring,
More informationStep-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry
Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high
More informationBiopharmaceutical Perspectives of Outsourcing: what are supply chain management issues and opportunities
1 Biopharmaceutical Perspectives of Outsourcing: what are supply chain management issues and opportunities Presented by Dr. Philipp Hess Supply Chain Management Issues and Opportunities 2 1. How do we
More informationChange-Point Analysis: A Powerful New Tool For Detecting Changes
Change-Point Analysis: A Powerful New Tool For Detecting Changes WAYNE A. TAYLOR Baxter Healthcare Corporation, Round Lake, IL 60073 Change-point analysis is a powerful new tool for determining whether
More informationData Mining Builds Process Understanding for Vaccine Manufacturing
Data Mining Builds Process Understanding for Vaccine Manufacturing WCBP 2009 Current Topics in Vaccine Development January 14, 2009 Julia O Neill, Principal Engineer Merck & Co., Inc. Global Vaccine Technology
More informationTesting Automated Manufacturing Processes
Testing Automated Manufacturing Processes (PLC based architecture) 1 ❶ Introduction. ❷ Regulations. ❸ CSV Automated Manufacturing Systems. ❹ PLCs Validation Methodology / Approach. ❺ Testing. ❻ Controls
More informationHarmonizing Change Control Processes Globally
Quality & Compliance Associates, LLC Harmonizing Change Control Processes Globally President Quality & Compliance Associates, LLC When We Deal In A Global Environment, How Do We Design A System That Addresses
More informationRisk analysis and management is the cornerstone
Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE This article presents a new type of risk tool. Risk Analysis and Mitigation Matrix (RAMM) was developed to be incorporated into a
More informationSite monitoring Transformed forever?
Site monitoring Transformed forever? June 2015 www.algorics.com Introduction: As the industry implementation of Risk Based Monitoring (RBM) progresses, one area to receive less focus than most has been
More informationVALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY
More informationICH guideline Q10 on pharmaceutical quality system
September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final
More informationSTOPPERS PREFILLABLE SYRINGE PLUNGERS. The New Definition of High-Quality Components
STOPPERS PREFILLABLE SYRINGE PLUNGERS The New Definition of High-Quality Components Proactively Partnering to Science and Technology West has adopted a continuous verification process that is unrivaled
More informationFusion Pro QbD-aligned DOE Software
Fusion Pro QbD-aligned DOE Software Statistical Experimental Design Analysis & Modeling Robustness Simulation Numerical & Graphical Optimization 2D, 3D, & 4D Visualization Graphics 100% aligned with Quality
More information[ABOUT THE AUTHOR. FDA Lifecycle Approach to Process Validation What, Why, and How? PQ Forum. Paul L. Pluta]
Paul L. Pluta] FDA Lifecycle Approach to Process Validation What, Why, and How? Paul L. Pluta PQ Forum provides a mechanism for validation practitioners to share information about Stage 2 process qualification
More informationLecture 2: Descriptive Statistics and Exploratory Data Analysis
Lecture 2: Descriptive Statistics and Exploratory Data Analysis Further Thoughts on Experimental Design 16 Individuals (8 each from two populations) with replicates Pop 1 Pop 2 Randomly sample 4 individuals
More informationGuidance for Industry
Guidance for Industry Q2B Validation of Analytical Procedures: Methodology November 1996 ICH Guidance for Industry Q2B Validation of Analytical Procedures: Methodology Additional copies are available from:
More informationCalculation of Alert Levels for Assessing Collection Center Donor Quality for PMF Evaluation
7 September 2010 Reference: EPI TF 10015 Calculation of Alert Levels for Assessing Collection Center Donor Quality for PMF Evaluation Background The quality and safety of plasma protein therapies and the
More informationWorkshop on Quality Risk Management Making Trials Fit for Purpose
Clinical Trials Transformation Initiative Workshop on Quality Risk Management Making Trials Fit for Purpose Andy Lee SVP, Global Clinical Operations, Genzyme Corporation August 23/24, 2011 Hyatt Regency,
More information